Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.32 |
| ▸ | GPX4 | P36969 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028872 | 0.87 | NAMPT (0.37) | NAMPTMTHFD2 | |
| SCHEMBL20817896 | 0.86 | NAMPT (0.44) | PARP1NAMPTMTHFD2 | |
| SCHEMBL21818928 | 0.71 | MTHFD2 (0.33) | PARP1FAAHTRPV1MTHFD2GPX4 | |
| SCHEMBL5367984 | 0.70 | PARP1 (0.66) | PARP1FAAHTRPV1MTHFD2GPX4 | |
| SCHEMBL30023116 | 0.70 | PARP1 (0.66) | PARP1FAAHTRPV1MTHFD2GPX4 | |
| SCHEMBL2075898 | 0.68 | KDM4E (0.45) | PARP1 | |
| SCHEMBL28646727 | 0.68 | P2RX7 (0.39) | — | |
| SCHEMBL28644919 | 0.68 | CREBBP (0.41) | — | |
| SCHEMBL17317850 | 0.68 | P2RX7 (0.39) | — | |
| SCHEMBL60542 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11225478-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| CN-110003200-B | P2X7 modulators | 詹森药业有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20200325138-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-15 | — | — | US | disclosed |
| US-10703749-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-07 | — | — | US | disclosed |
| EP-3495365-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| US-20190092770-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-28 | — | — | US | disclosed |
| US-10150765-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-11 | — | — | US | disclosed |
| EP-3239151-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2017-11-01 | — | — | EP | disclosed |
| EP-2970267-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-24 | — | — | EP | disclosed |
| US-20160376271-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV | 2016-12-29 | — | — | US | disclosed |
| US-9464084-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-11 | — | — | US | disclosed |
| US-20160039809-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| EP-2970267-A1 | P2X7 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150322062-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-9066946-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| WO-2014152604-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325138-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-10150765-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-20160376271-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-20190092770-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-11225478-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-20160039809-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RX5 | PARP1 2787/4885NAMPT 861/4885FAAH 1969/4885 |
| US-20150322062-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-10703749-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
| US-20140275015-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NAMPT 761/4885FAAH 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.